Layoffs
More than 600 employees will lose their jobs as the companies reshape their corporate strategies.
In addition to the layoffs, Acer said it has halted pre-commercial activities surrounding Edsivo due to the FDA’s rejection last month.
A month after beleaguered Merrimack Pharmaceuticals announced it was terminating its staff and leadership team, the company’s chief executive officer and chief financial officer have resigned their positions. But, they are both remaining with the company as high-paid consultants.
Financial details of the deal were not disclosed, but Lonza said it plans to retain the Novartis employees currently working at the facility.
Two months after taking over as interim chief executive officer of Bay Area-based uBiome, John Rakow is stepping down from the company that has been under scrutiny from the Federal Bureau of Investigation (FBI).
Following an operational review, ImmunoGen will prioritize continued development of mirvetuximab, as well as a select portfolio of three earlier-stage product candidates.
Conatus indicated that it is considering a sale of the company as part of an exploration of strategic alternatives. It is already implementing a restructuring plan that will cut 40% of staff and suspend development of its inflammasome compound CTS-2090.
The intention is to focus its research efforts on cancer, immunology, rare diseases and vaccines. The changes will result in the loss of 466 jobs in the two countries.
Hundreds lose their jobs as companies close facilities and shift business focuses.
Help us identify the leading employers in the life science industry! We want to uncover who leads in key areas like diversity, culture, unique benefits and, of course, who are the 2019 Life Sciences Ideal Employers.
PRESS RELEASES
